antisense therapy

(redirected from Antisense drugs)

an·ti·sense ther·a·py

use of antisense DNA for the inhibition of transcription or translation of a specific gene or gene product for therapeutic purposes.
References in periodicals archive ?
Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.
The patent claims broadly cover antisense drugs with "chimeric" or "gapmer" structures, including Isis' proprietary second-generation structures and the compositions of numerous other antisense compounds.
Isis and Lilly will continue to advance antisense drugs identified during the previous collaboration, and continue their efforts to develop and refine antisense technologies.
Second-generation antisense drugs offer greater potency, enhanced tolerability, and improved dosing convenience compared to first-generation antisense drugs.
Inhalation could be used as the entrance of antisense drugs into the body.
The promise of antisense drugs lies in the theory that they work on a specific target disease without causing significant side effects.
announced today a cross-license agreement for the development of antisense drugs targeting p53, a well-studied human protein that controls cellular response to genetic damage.
Antisense drugs are short, chemically-modified RNA-like and DNA-like molecules that scientists design to complement a small, specific segment of messenger RNA.
a San Diego-based biotechnology company, to develop so-called antisense drugs to block the activity of bcl-2.
AVI also has three ongoing Cooperative Research and Development Agreements (CRADAs) with various government agencies underway to test its antisense drugs against a variety of infectious viruses:
We are optimistic that through the combination of Amgen's experience in discovering novel biopharmaceutical products and Isis' expertise in antisense technology, the prospects of new antisense drugs reaching the market in the coming years has been greatly enhanced.
The potential market for antisense drugs is huge, they gush -- about $25 billion by 1992, according to some company estimates.